TalkMed Group Ltd. (SG:5G3) has released an update.
TalkMed Group Ltd. has been added as a defendant in ongoing legal proceedings following the 2021 divestment of its majority stake in Stem Med. The proceedings involve multiple parties, including former subsidiary Stem Med and other vendors, and center around allegations of breaches of fiduciary duties, lease agreements, and a Sale and Purchase Agreement. This development follows a series of claims and counterclaims between the involved parties, highlighting complex legal disputes post-divestment.
For further insights into SG:5G3 stock, check out TipRanks’ Stock Analysis page.
